add-aspirin trial: a phase iii, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors

Phase ii study of the antibody-drug conjugate tak-264 (mln0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase c

A phase ii study of antibody-drug conjugate, tak-264 (mln0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase c

Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis

Abstract 3960: combined circulating tumour cell (ctc) and circulating tumor dna (ctdna) analysis of blood from patients with pancreatic cancer

Adi-peg 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Aspirin as an adjuvant treatment for cancer: feasibility results from the add-aspirin randomised trial